BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo Sells 709,502 Shares

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 709,502 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $2.73, for a total value of $1,936,940.46. Following the completion of the sale, the director now directly owns 1,759,262 shares in the company, valued at $4,802,785.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of BioDelivery Sciences International, Inc. (BDSI) traded up $0.10 during midday trading on Monday, reaching $2.30. The company’s stock had a trading volume of 538,385 shares, compared to its average volume of 567,561. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International, Inc. has a 12 month low of $1.55 and a 12 month high of $3.60. The stock has a market cap of $128.53, a P/E ratio of 25.56 and a beta of 0.50.

A number of research firms have weighed in on BDSI. Piper Jaffray Companies set a $4.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Roth Capital set a $5.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, November 13th. Seaport Global Securities assumed coverage on BioDelivery Sciences International in a research report on Friday, January 26th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. BioDelivery Sciences International presently has an average rating of “Buy” and a consensus target price of $4.38.

Several large investors have recently added to or reduced their stakes in the company. Royce & Associates LP boosted its position in shares of BioDelivery Sciences International by 43.0% during the 4th quarter. Royce & Associates LP now owns 1,848,600 shares of the specialty pharmaceutical company’s stock worth $5,453,000 after acquiring an additional 555,800 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of BioDelivery Sciences International by 88.9% during the 4th quarter. Wells Fargo & Company MN now owns 67,081 shares of the specialty pharmaceutical company’s stock worth $198,000 after acquiring an additional 31,575 shares in the last quarter. Krilogy Financial LLC boosted its position in shares of BioDelivery Sciences International by 28.8% during the 3rd quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after acquiring an additional 30,000 shares in the last quarter. Stonepine Capital Management LLC boosted its position in shares of BioDelivery Sciences International by 11.2% in the 3rd quarter. Stonepine Capital Management LLC now owns 3,867,400 shares of the specialty pharmaceutical company’s stock valued at $11,409,000 after purchasing an additional 389,727 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in shares of BioDelivery Sciences International in the 3rd quarter valued at about $116,000. 44.16% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/12/mark-a-sirgo-sells-709502-shares-of-biodelivery-sciences-international-inc-bdsi-stock-updated-updated-updated.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply